 Ross Kedl
Concepts (485)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 63 | 2025 | 907 | 8.450 |
Why?
| | Immunologic Memory | 29 | 2025 | 353 | 5.160 |
Why?
| | Dendritic Cells | 30 | 2022 | 483 | 3.930 |
Why?
| | T-Lymphocytes | 24 | 2024 | 1975 | 2.320 |
Why?
| | Lymphocyte Activation | 27 | 2022 | 1134 | 2.130 |
Why?
| | Vaccines, Subunit | 6 | 2021 | 49 | 2.050 |
Why?
| | Antigen Presentation | 10 | 2017 | 218 | 1.920 |
Why?
| | CD40 Antigens | 12 | 2021 | 88 | 1.730 |
Why?
| | Antigens | 10 | 2017 | 352 | 1.700 |
Why?
| | Mice, Inbred C57BL | 51 | 2025 | 5733 | 1.550 |
Why?
| | Adjuvants, Immunologic | 15 | 2025 | 229 | 1.540 |
Why?
| | Interleukin-15 | 7 | 2025 | 101 | 1.450 |
Why?
| | Membrane Glycoproteins | 11 | 2014 | 496 | 1.400 |
Why?
| | CD27 Ligand | 4 | 2015 | 9 | 1.400 |
Why?
| | Vaccines | 6 | 2019 | 400 | 1.370 |
Why?
| | T-Lymphocyte Subsets | 8 | 2014 | 415 | 1.320 |
Why?
| | Mice | 77 | 2025 | 17705 | 1.260 |
Why?
| | Interleukins | 5 | 2021 | 250 | 1.250 |
Why?
| | Interferon Type I | 7 | 2017 | 140 | 1.220 |
Why?
| | Animals | 97 | 2025 | 36882 | 1.170 |
Why?
| | Interleukin-27 | 4 | 2024 | 13 | 1.150 |
Why?
| | CD4-Positive T-Lymphocytes | 15 | 2021 | 1083 | 1.130 |
Why?
| | Lymph Nodes | 6 | 2017 | 483 | 1.130 |
Why?
| | Listeria monocytogenes | 6 | 2025 | 121 | 1.070 |
Why?
| | CD8 Antigens | 4 | 2019 | 74 | 1.070 |
Why?
| | Mice, Transgenic | 21 | 2021 | 2156 | 1.000 |
Why?
| | Ovalbumin | 14 | 2025 | 186 | 1.000 |
Why?
| | Immunity, Innate | 7 | 2022 | 819 | 1.000 |
Why?
| | Mice, Knockout | 25 | 2025 | 2999 | 0.990 |
Why?
| | Toll-Like Receptor 7 | 10 | 2014 | 39 | 0.940 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 3 | 2015 | 28 | 0.920 |
Why?
| | Interleukin-12 | 8 | 2025 | 120 | 0.920 |
Why?
| | GTP Phosphohydrolases | 1 | 2025 | 92 | 0.890 |
Why?
| | T-Lymphocytes, Helper-Inducer | 3 | 2021 | 134 | 0.890 |
Why?
| | Emergency Responders | 2 | 2021 | 35 | 0.850 |
Why?
| | Melanoma, Experimental | 6 | 2025 | 111 | 0.790 |
Why?
| | Cross-Priming | 4 | 2011 | 16 | 0.780 |
Why?
| | Mitochondrial Proteins | 1 | 2025 | 257 | 0.780 |
Why?
| | Listeriosis | 3 | 2025 | 70 | 0.770 |
Why?
| | Cancer Vaccines | 7 | 2016 | 164 | 0.770 |
Why?
| | B-Lymphocytes | 4 | 2025 | 845 | 0.750 |
Why?
| | Epitopes, T-Lymphocyte | 8 | 2021 | 182 | 0.730 |
Why?
| | Asymptomatic Infections | 1 | 2021 | 33 | 0.700 |
Why?
| | Immunity | 2 | 2019 | 139 | 0.690 |
Why?
| | Signal Transduction | 16 | 2025 | 5047 | 0.660 |
Why?
| | Lymphocyte Depletion | 3 | 2019 | 136 | 0.650 |
Why?
| | Adaptive Immunity | 5 | 2020 | 165 | 0.640 |
Why?
| | Poly I-C | 6 | 2015 | 63 | 0.600 |
Why?
| | Immunity, Cellular | 5 | 2015 | 267 | 0.590 |
Why?
| | Antigens, Viral | 2 | 2014 | 178 | 0.580 |
Why?
| | Interferon-gamma | 4 | 2023 | 782 | 0.570 |
Why?
| | Cell Proliferation | 7 | 2025 | 2456 | 0.570 |
Why?
| | Immunotherapy, Adoptive | 2 | 2025 | 330 | 0.550 |
Why?
| | Cell Differentiation | 12 | 2023 | 1985 | 0.550 |
Why?
| | Toll-Like Receptors | 7 | 2020 | 186 | 0.540 |
Why?
| | Receptors, Antigen, T-Cell | 9 | 2020 | 716 | 0.530 |
Why?
| | Adoptive Transfer | 11 | 2020 | 220 | 0.530 |
Why?
| | Aminoquinolines | 4 | 2005 | 19 | 0.530 |
Why?
| | Vaccination | 9 | 2021 | 1428 | 0.510 |
Why?
| | Bystander Effect | 1 | 2016 | 16 | 0.500 |
Why?
| | Receptors, Cell Surface | 5 | 2005 | 391 | 0.490 |
Why?
| | Receptor, Interferon alpha-beta | 3 | 2017 | 34 | 0.490 |
Why?
| | Interleukin-2 Receptor beta Subunit | 3 | 2025 | 27 | 0.480 |
Why?
| | Cell Movement | 8 | 2022 | 964 | 0.480 |
Why?
| | Endothelium, Lymphatic | 1 | 2015 | 11 | 0.480 |
Why?
| | Cytotoxicity, Immunologic | 7 | 2025 | 222 | 0.470 |
Why?
| | Squalene | 1 | 2015 | 7 | 0.460 |
Why?
| | H-2 Antigens | 5 | 2016 | 115 | 0.450 |
Why?
| | Breeding | 1 | 2014 | 64 | 0.450 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 258 | 0.440 |
Why?
| | Caspase 1 | 1 | 2015 | 143 | 0.440 |
Why?
| | Housing, Animal | 1 | 2014 | 46 | 0.430 |
Why?
| | Bacterial Vaccines | 1 | 2014 | 63 | 0.430 |
Why?
| | OX40 Ligand | 2 | 2011 | 10 | 0.430 |
Why?
| | Antigens, Neoplasm | 5 | 2018 | 316 | 0.430 |
Why?
| | Caspases | 1 | 2015 | 242 | 0.420 |
Why?
| | Immunization | 9 | 2020 | 404 | 0.420 |
Why?
| | Viral Vaccines | 2 | 2014 | 107 | 0.410 |
Why?
| | Interleukin-18 | 1 | 2015 | 236 | 0.410 |
Why?
| | Cytokines | 13 | 2019 | 2070 | 0.400 |
Why?
| | Cell Lineage | 3 | 2013 | 352 | 0.400 |
Why?
| | Toll-Like Receptor 4 | 1 | 2015 | 272 | 0.390 |
Why?
| | Endothelial Cells | 1 | 2017 | 784 | 0.380 |
Why?
| | Receptors, OX40 | 1 | 2011 | 15 | 0.370 |
Why?
| | Tumor Necrosis Factors | 1 | 2011 | 11 | 0.370 |
Why?
| | Spike Glycoprotein, Coronavirus | 3 | 2022 | 118 | 0.370 |
Why?
| | Up-Regulation | 5 | 2022 | 838 | 0.370 |
Why?
| | T-Cell Antigen Receptor Specificity | 4 | 2016 | 50 | 0.370 |
Why?
| | Spleen | 8 | 2019 | 514 | 0.370 |
Why?
| | Virus Diseases | 1 | 2014 | 212 | 0.360 |
Why?
| | Chemokines | 4 | 2020 | 225 | 0.360 |
Why?
| | Antibodies, Viral | 6 | 2023 | 646 | 0.360 |
Why?
| | Immunity, Humoral | 3 | 2023 | 117 | 0.360 |
Why?
| | Vaccinia | 3 | 2018 | 20 | 0.360 |
Why?
| | Cells, Cultured | 11 | 2019 | 4136 | 0.360 |
Why?
| | Orthomyxoviridae Infections | 3 | 2021 | 67 | 0.350 |
Why?
| | Vaccines, Conjugate | 2 | 2010 | 64 | 0.350 |
Why?
| | Antigen-Presenting Cells | 5 | 2018 | 157 | 0.330 |
Why?
| | Pancreatic Neoplasms | 3 | 2023 | 832 | 0.320 |
Why?
| | Female | 38 | 2025 | 73002 | 0.320 |
Why?
| | Humans | 44 | 2025 | 136965 | 0.310 |
Why?
| | Th1 Cells | 5 | 2019 | 141 | 0.300 |
Why?
| | Industry | 1 | 2009 | 68 | 0.290 |
Why?
| | Career Mobility | 1 | 2009 | 70 | 0.290 |
Why?
| | Lymphocyte Count | 4 | 2021 | 147 | 0.280 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 3 | 2017 | 41 | 0.280 |
Why?
| | Myeloid Cells | 4 | 2021 | 149 | 0.260 |
Why?
| | Career Choice | 1 | 2009 | 226 | 0.260 |
Why?
| | Skin Neoplasms | 2 | 2022 | 842 | 0.260 |
Why?
| | Radiation Chimera | 3 | 2014 | 28 | 0.250 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2006 | 68 | 0.250 |
Why?
| | Universities | 1 | 2009 | 442 | 0.250 |
Why?
| | Toxoplasmosis | 2 | 2024 | 40 | 0.250 |
Why?
| | Toxoplasma | 2 | 2024 | 42 | 0.250 |
Why?
| | Oligopeptides | 2 | 2012 | 269 | 0.240 |
Why?
| | Viral Proteins | 2 | 2001 | 359 | 0.240 |
Why?
| | Binding, Competitive | 2 | 2003 | 194 | 0.240 |
Why?
| | Neoplasm Transplantation | 3 | 2006 | 250 | 0.230 |
Why?
| | CD11b Antigen | 2 | 2014 | 62 | 0.230 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2025 | 43 | 0.230 |
Why?
| | Mice, 129 Strain | 2 | 2017 | 87 | 0.230 |
Why?
| | Mitochondrial Dynamics | 1 | 2025 | 39 | 0.230 |
Why?
| | CD11c Antigen | 2 | 2008 | 41 | 0.220 |
Why?
| | Repressor Proteins | 3 | 2017 | 422 | 0.220 |
Why?
| | Mice, Inbred BALB C | 10 | 2020 | 1256 | 0.220 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 162 | 0.210 |
Why?
| | Monocytes | 4 | 2024 | 562 | 0.210 |
Why?
| | B7-H1 Antigen | 4 | 2021 | 213 | 0.210 |
Why?
| | Nanoparticles | 2 | 2025 | 467 | 0.210 |
Why?
| | Influenza A virus | 2 | 2021 | 110 | 0.210 |
Why?
| | Immunophenotyping | 3 | 2019 | 323 | 0.200 |
Why?
| | Peptide Fragments | 4 | 2016 | 690 | 0.200 |
Why?
| | Cell Adhesion Molecules | 2 | 2022 | 176 | 0.200 |
Why?
| | Omentum | 1 | 2022 | 10 | 0.200 |
Why?
| | Egg Proteins | 2 | 2001 | 17 | 0.200 |
Why?
| | Chemokine CXCL10 | 2 | 2022 | 38 | 0.190 |
Why?
| | Influenza Vaccines | 3 | 2025 | 531 | 0.190 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 44 | 0.190 |
Why?
| | Graft Rejection | 2 | 2017 | 571 | 0.190 |
Why?
| | Imidazoles | 5 | 2014 | 235 | 0.190 |
Why?
| | Transforming Growth Factor beta | 2 | 2019 | 483 | 0.190 |
Why?
| | Gene Expression | 3 | 2016 | 1480 | 0.190 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 12 | 0.190 |
Why?
| | Lung | 6 | 2021 | 4035 | 0.190 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 25 | 0.190 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 15 | 0.180 |
Why?
| | Transcription Factors | 4 | 2023 | 1705 | 0.180 |
Why?
| | Immunotherapy | 5 | 2023 | 627 | 0.180 |
Why?
| | Microspheres | 2 | 2021 | 134 | 0.180 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1382 | 0.180 |
Why?
| | Portraits as Topic | 1 | 2021 | 1 | 0.180 |
Why?
| | Disease Models, Animal | 6 | 2025 | 4276 | 0.180 |
Why?
| | Microfilament Proteins | 1 | 2022 | 133 | 0.180 |
Why?
| | Receptors, CCR2 | 1 | 2021 | 39 | 0.180 |
Why?
| | RNA, Messenger | 4 | 2025 | 2788 | 0.180 |
Why?
| | Mutation | 2 | 2025 | 3975 | 0.180 |
Why?
| | Immunologic Factors | 1 | 2003 | 236 | 0.180 |
Why?
| | Male | 21 | 2025 | 67386 | 0.170 |
Why?
| | Receptors, Virus | 1 | 2021 | 93 | 0.170 |
Why?
| | Immunoglobulin M | 2 | 2022 | 288 | 0.170 |
Why?
| | Luminescent Proteins | 1 | 2001 | 181 | 0.170 |
Why?
| | Immunoassay | 1 | 2021 | 113 | 0.170 |
Why?
| | Lipids | 1 | 2025 | 678 | 0.170 |
Why?
| | Immunity, Mucosal | 1 | 2021 | 96 | 0.170 |
Why?
| | Transcriptional Activation | 2 | 2022 | 371 | 0.170 |
Why?
| | Specimen Handling | 1 | 2022 | 181 | 0.160 |
Why?
| | Interleukin-2 | 6 | 2025 | 449 | 0.160 |
Why?
| | Cell Communication | 4 | 2013 | 315 | 0.160 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 315 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1229 | 0.160 |
Why?
| | Actins | 1 | 2022 | 415 | 0.160 |
Why?
| | Primary Cell Culture | 2 | 2021 | 171 | 0.160 |
Why?
| | Phosphoproteins | 1 | 2022 | 337 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2022 | 220 | 0.160 |
Why?
| | Integrin alpha Chains | 3 | 2019 | 24 | 0.160 |
Why?
| | Glycoproteins | 1 | 2001 | 356 | 0.160 |
Why?
| | Macrophages | 2 | 2021 | 1540 | 0.160 |
Why?
| | Liposomes | 5 | 2025 | 217 | 0.160 |
Why?
| | Disease Resistance | 1 | 2019 | 34 | 0.150 |
Why?
| | Joints | 1 | 2020 | 104 | 0.150 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2019 | 7 | 0.150 |
Why?
| | Chikungunya Fever | 1 | 2020 | 79 | 0.150 |
Why?
| | Allergens | 2 | 2021 | 394 | 0.150 |
Why?
| | Homeostasis | 2 | 2016 | 616 | 0.150 |
Why?
| | Chikungunya virus | 1 | 2020 | 80 | 0.150 |
Why?
| | Aerobiosis | 1 | 2018 | 22 | 0.150 |
Why?
| | T-Box Domain Proteins | 1 | 2019 | 98 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 189 | 0.150 |
Why?
| | Antibodies, Monoclonal | 4 | 2019 | 1412 | 0.150 |
Why?
| | Immune Tolerance | 3 | 2012 | 363 | 0.150 |
Why?
| | Mitochondria | 1 | 2025 | 949 | 0.150 |
Why?
| | Hypersensitivity | 1 | 2021 | 249 | 0.140 |
Why?
| | Flow Cytometry | 5 | 2016 | 1189 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 457 | 0.140 |
Why?
| | Gene Expression Regulation | 6 | 2013 | 2574 | 0.140 |
Why?
| | Peptides | 5 | 2013 | 975 | 0.140 |
Why?
| | Cell Membrane | 1 | 2001 | 710 | 0.140 |
Why?
| | Vaccines, DNA | 2 | 2009 | 32 | 0.140 |
Why?
| | Vaccinia virus | 3 | 2010 | 43 | 0.140 |
Why?
| | Autoimmunity | 3 | 2025 | 897 | 0.140 |
Why?
| | Lymphocytes | 2 | 2022 | 389 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 552 | 0.130 |
Why?
| | Interleukin-10 | 1 | 2019 | 299 | 0.130 |
Why?
| | Antigens, CD | 4 | 2019 | 527 | 0.130 |
Why?
| | Gene Products, gag | 3 | 2006 | 36 | 0.130 |
Why?
| | Killer Cells, Natural | 2 | 2019 | 448 | 0.130 |
Why?
| | Friend murine leukemia virus | 1 | 2017 | 30 | 0.130 |
Why?
| | Transplantation Tolerance | 1 | 2017 | 38 | 0.130 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2018 | 165 | 0.130 |
Why?
| | Cytidine Deaminase | 1 | 2017 | 61 | 0.130 |
Why?
| | Glycolysis | 1 | 2018 | 319 | 0.130 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2017 | 64 | 0.130 |
Why?
| | Antibodies | 3 | 2015 | 406 | 0.130 |
Why?
| | Melanoma | 2 | 2022 | 760 | 0.120 |
Why?
| | Epitopes | 3 | 2007 | 476 | 0.120 |
Why?
| | Myeloid Differentiation Factor 88 | 3 | 2011 | 100 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2016 | 335 | 0.120 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2016 | 163 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 203 | 0.120 |
Why?
| | Caspases, Initiator | 1 | 2015 | 16 | 0.120 |
Why?
| | AIDS Vaccines | 2 | 2005 | 53 | 0.120 |
Why?
| | DNA-Binding Proteins | 2 | 2018 | 1472 | 0.110 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2015 | 47 | 0.110 |
Why?
| | Antibody Formation | 2 | 2013 | 294 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2022 | 869 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 427 | 0.110 |
Why?
| | Toll-Like Receptor 9 | 2 | 2006 | 32 | 0.110 |
Why?
| | Immunoglobulin G | 5 | 2022 | 892 | 0.110 |
Why?
| | Reoviridae | 1 | 1995 | 37 | 0.110 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 374 | 0.110 |
Why?
| | Skin Transplantation | 1 | 2015 | 82 | 0.110 |
Why?
| | Smallpox Vaccine | 1 | 2014 | 23 | 0.110 |
Why?
| | STAT Transcription Factors | 1 | 2014 | 16 | 0.110 |
Why?
| | Receptors, Cytokine | 1 | 2014 | 36 | 0.110 |
Why?
| | Coculture Techniques | 1 | 2015 | 240 | 0.110 |
Why?
| | Receptors, Interleukin | 1 | 2014 | 45 | 0.110 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2014 | 83 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2017 | 300 | 0.110 |
Why?
| | Pandemics | 1 | 2023 | 1630 | 0.110 |
Why?
| | Tumor Cells, Cultured | 3 | 2021 | 942 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1995 | 392 | 0.110 |
Why?
| | Capsid Proteins | 1 | 1995 | 94 | 0.110 |
Why?
| | Colorado | 2 | 2021 | 4542 | 0.110 |
Why?
| | Virus Replication | 1 | 2017 | 518 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 3 | 2013 | 561 | 0.100 |
Why?
| | Gangliosides | 1 | 2013 | 21 | 0.100 |
Why?
| | Growth Hormone | 1 | 2013 | 100 | 0.100 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 2013 | 11 | 0.100 |
Why?
| | Autoantigens | 1 | 2016 | 421 | 0.100 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2013 | 17 | 0.100 |
Why?
| | Genes, MHC Class II | 1 | 2013 | 75 | 0.100 |
Why?
| | Transplantation Chimera | 1 | 2013 | 58 | 0.100 |
Why?
| | Phenotype | 2 | 2019 | 3148 | 0.100 |
Why?
| | Clone Cells | 4 | 2001 | 263 | 0.100 |
Why?
| | Whole-Body Irradiation | 1 | 2013 | 78 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2014 | 268 | 0.100 |
Why?
| | Muramidase | 1 | 2012 | 80 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 100 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2007 | 365 | 0.090 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2025 | 384 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2013 | 1343 | 0.090 |
Why?
| | Antigenic Variation | 1 | 2011 | 10 | 0.090 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 13 | 0.090 |
Why?
| | Receptors, Interleukin-12 | 1 | 2011 | 7 | 0.090 |
Why?
| | Thymus Gland | 1 | 2013 | 313 | 0.090 |
Why?
| | Toll-Like Receptor 3 | 2 | 2014 | 28 | 0.090 |
Why?
| | Myocarditis | 1 | 2012 | 98 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3393 | 0.090 |
Why?
| | Transplantation, Homologous | 3 | 2017 | 409 | 0.090 |
Why?
| | Immunoglobulin E | 1 | 2012 | 323 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 1995 | 424 | 0.090 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 96 | 0.090 |
Why?
| | Nasal Mucosa | 1 | 2011 | 105 | 0.080 |
Why?
| | Hyaluronan Receptors | 2 | 2009 | 102 | 0.080 |
Why?
| | Nucleic Acids | 1 | 2011 | 70 | 0.080 |
Why?
| | Time Factors | 1 | 2021 | 6786 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 985 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 873 | 0.080 |
Why?
| | Macaca mulatta | 3 | 2019 | 182 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2266 | 0.080 |
Why?
| | Toll-Like Receptor 5 | 1 | 2009 | 14 | 0.080 |
Why?
| | Granzymes | 2 | 2022 | 49 | 0.080 |
Why?
| | Polyethyleneimine | 1 | 2009 | 18 | 0.080 |
Why?
| | Organ Specificity | 2 | 2001 | 305 | 0.080 |
Why?
| | Toll-Like Receptor 8 | 2 | 2006 | 6 | 0.080 |
Why?
| | Liver | 2 | 2016 | 1867 | 0.080 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 206 | 0.080 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2139 | 0.080 |
Why?
| | Injections, Intravenous | 2 | 2013 | 197 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 463 | 0.070 |
Why?
| | Bronchial Hyperreactivity | 1 | 2009 | 103 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 2 | 2002 | 622 | 0.070 |
Why?
| | Kupffer Cells | 1 | 2008 | 49 | 0.070 |
Why?
| | Lectins, C-Type | 2 | 2020 | 64 | 0.070 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 451 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1452 | 0.070 |
Why?
| | Baculoviridae | 1 | 2008 | 44 | 0.070 |
Why?
| | Protein Binding | 2 | 2022 | 2223 | 0.070 |
Why?
| | Insecta | 1 | 2008 | 70 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2012 | 781 | 0.070 |
Why?
| | B7-1 Antigen | 3 | 2009 | 58 | 0.070 |
Why?
| | Interferon Inducers | 2 | 2008 | 8 | 0.070 |
Why?
| | Major Histocompatibility Complex | 2 | 2008 | 230 | 0.070 |
Why?
| | Saccharomyces cerevisiae | 1 | 2012 | 551 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 667 | 0.070 |
Why?
| | Research Personnel | 1 | 2009 | 186 | 0.070 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 619 | 0.070 |
Why?
| | Histocompatibility Antigen H-2D | 2 | 2008 | 21 | 0.060 |
Why?
| | Injections, Intradermal | 1 | 2006 | 12 | 0.060 |
Why?
| | Oleic Acids | 1 | 2006 | 12 | 0.060 |
Why?
| | Mannitol | 1 | 2006 | 38 | 0.060 |
Why?
| | Injections, Intraperitoneal | 2 | 2013 | 113 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2009 | 508 | 0.060 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2022 | 171 | 0.060 |
Why?
| | Immunosuppressive Agents | 2 | 2009 | 861 | 0.060 |
Why?
| | HIV Antigens | 1 | 2005 | 18 | 0.060 |
Why?
| | Neoplasms, Experimental | 1 | 2006 | 174 | 0.060 |
Why?
| | Oligodeoxyribonucleotides | 4 | 2006 | 142 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1027 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 57 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2552 | 0.060 |
Why?
| | Forkhead Box Protein O1 | 1 | 2025 | 33 | 0.060 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2025 | 40 | 0.060 |
Why?
| | Cell Adhesion | 1 | 2006 | 465 | 0.060 |
Why?
| | CD40 Ligand | 2 | 2018 | 41 | 0.060 |
Why?
| | Genes, Reporter | 2 | 2002 | 271 | 0.050 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2004 | 39 | 0.050 |
Why?
| | Transfection | 3 | 2019 | 934 | 0.050 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 802 | 0.050 |
Why?
| | Ovarian Neoplasms | 1 | 2009 | 566 | 0.050 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2023 | 81 | 0.050 |
Why?
| | Neoplasms | 2 | 2009 | 2698 | 0.050 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 21 | 0.050 |
Why?
| | Asthma | 2 | 2012 | 1873 | 0.050 |
Why?
| | Leukemia | 1 | 2025 | 240 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2542 | 0.050 |
Why?
| | Ubiquitin C | 1 | 2001 | 3 | 0.050 |
Why?
| | Interphase | 2 | 1999 | 32 | 0.050 |
Why?
| | Pregnancy | 1 | 2014 | 6736 | 0.050 |
Why?
| | THP-1 Cells | 1 | 2021 | 19 | 0.050 |
Why?
| | CTLA-4 Antigen | 2 | 2019 | 97 | 0.050 |
Why?
| | Cytoskeletal Proteins | 1 | 2022 | 155 | 0.050 |
Why?
| | Lymph Node Excision | 1 | 2022 | 168 | 0.050 |
Why?
| | Polymerization | 1 | 2022 | 127 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 232 | 0.040 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2001 | 139 | 0.040 |
Why?
| | Transcriptome | 2 | 2019 | 966 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2001 | 756 | 0.040 |
Why?
| | World Health Organization | 1 | 2022 | 124 | 0.040 |
Why?
| | Macromolecular Substances | 1 | 2001 | 226 | 0.040 |
Why?
| | Cell Line | 2 | 2005 | 2855 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 248 | 0.040 |
Why?
| | Middle Aged | 3 | 2021 | 33226 | 0.040 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2020 | 15 | 0.040 |
Why?
| | Tumor Burden | 1 | 2022 | 305 | 0.040 |
Why?
| | Receptors, Mitogen | 1 | 2020 | 8 | 0.040 |
Why?
| | Acrylic Resins | 1 | 2020 | 46 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 202 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 193 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 203 | 0.040 |
Why?
| | Keratinocytes | 1 | 2021 | 249 | 0.040 |
Why?
| | Green Fluorescent Proteins | 1 | 2001 | 396 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 682 | 0.040 |
Why?
| | Mice, Inbred Strains | 1 | 2000 | 409 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2022 | 1215 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Lipopolysaccharides | 4 | 2006 | 878 | 0.040 |
Why?
| | Gene Expression Profiling | 3 | 2002 | 1747 | 0.040 |
Why?
| | Arthritis | 1 | 2020 | 94 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 52 | 0.040 |
Why?
| | Clonal Anergy | 1 | 1999 | 52 | 0.040 |
Why?
| | HIV-1 | 1 | 2005 | 866 | 0.040 |
Why?
| | Aged | 2 | 2016 | 23803 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 660 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1999 | 139 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 203 | 0.040 |
Why?
| | Survival Analysis | 1 | 2022 | 1278 | 0.040 |
Why?
| | Siblings | 1 | 2019 | 215 | 0.040 |
Why?
| | Plasmids | 2 | 2011 | 358 | 0.030 |
Why?
| | Immunoconjugates | 1 | 1999 | 115 | 0.030 |
Why?
| | Cations | 2 | 2009 | 83 | 0.030 |
Why?
| | Genome | 1 | 2000 | 300 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2019 | 215 | 0.030 |
Why?
| | Acute Disease | 1 | 2020 | 993 | 0.030 |
Why?
| | Adult | 2 | 2021 | 37715 | 0.030 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 191 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2001 | 1235 | 0.030 |
Why?
| | Skin | 1 | 2021 | 746 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2016 | 41 | 0.030 |
Why?
| | Cell Separation | 2 | 2012 | 314 | 0.030 |
Why?
| | Arenaviridae Infections | 1 | 2016 | 17 | 0.030 |
Why?
| | Biomarkers | 2 | 2021 | 4095 | 0.030 |
Why?
| | Lymphocytic choriomeningitis virus | 1 | 2016 | 31 | 0.030 |
Why?
| | Carboxymethylcellulose Sodium | 1 | 2015 | 3 | 0.030 |
Why?
| | Polylysine | 1 | 2015 | 17 | 0.030 |
Why?
| | CpG Islands | 2 | 2006 | 158 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 2015 | 125 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2001 | 2900 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2016 | 188 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1774 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2708 | 0.030 |
Why?
| | Down-Regulation | 2 | 2011 | 633 | 0.030 |
Why?
| | Hypodermoclysis | 1 | 2013 | 4 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 757 | 0.030 |
Why?
| | Stem Cells | 1 | 1998 | 595 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1591 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 104 | 0.030 |
Why?
| | Species Specificity | 1 | 1995 | 583 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1045 | 0.020 |
Why?
| | Immunological Synapses | 1 | 2012 | 16 | 0.020 |
Why?
| | Interleukin-1 | 2 | 2012 | 962 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 2012 | 113 | 0.020 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 320 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 639 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 347 | 0.020 |
Why?
| | Interferon-alpha | 2 | 2005 | 199 | 0.020 |
Why?
| | Inflammation | 2 | 2020 | 2831 | 0.020 |
Why?
| | Particle Size | 1 | 2013 | 391 | 0.020 |
Why?
| | Cattle | 1 | 1995 | 982 | 0.020 |
Why?
| | Clodronic Acid | 1 | 2012 | 18 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2012 | 76 | 0.020 |
Why?
| | Aerosols | 1 | 2012 | 177 | 0.020 |
Why?
| | Diphtheria Toxin | 1 | 2012 | 66 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 116 | 0.020 |
Why?
| | Melioidosis | 1 | 2011 | 5 | 0.020 |
Why?
| | Burkholderia pseudomallei | 1 | 2011 | 10 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 298 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 150 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2012 | 582 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2011 | 89 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 384 | 0.020 |
Why?
| | Th17 Cells | 1 | 2012 | 108 | 0.020 |
Why?
| | Lipoproteins | 1 | 2012 | 166 | 0.020 |
Why?
| | Cysteine | 1 | 2012 | 202 | 0.020 |
Why?
| | Pulmonary Emphysema | 1 | 2013 | 288 | 0.020 |
Why?
| | Phylogeny | 1 | 1995 | 1003 | 0.020 |
Why?
| | Weight Gain | 1 | 2013 | 535 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2012 | 369 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2009 | 48 | 0.020 |
Why?
| | Echocardiography | 1 | 2012 | 639 | 0.020 |
Why?
| | Prostaglandin D2 | 1 | 2008 | 23 | 0.020 |
Why?
| | Heart | 1 | 2012 | 609 | 0.020 |
Why?
| | Cell Death | 2 | 2001 | 370 | 0.020 |
Why?
| | Ischemia | 1 | 2012 | 407 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2009 | 140 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2008 | 38 | 0.020 |
Why?
| | Metabolomics | 1 | 2013 | 681 | 0.020 |
Why?
| | Dinoprostone | 1 | 2008 | 191 | 0.020 |
Why?
| | Cell Survival | 2 | 2002 | 1124 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 303 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10363 | 0.020 |
Why?
| | Zymosan | 1 | 2006 | 66 | 0.020 |
Why?
| | Nucleocapsid Proteins | 1 | 2005 | 26 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 3258 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2008 | 656 | 0.010 |
Why?
| | Primates | 1 | 2005 | 139 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2019 | 10664 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5544 | 0.010 |
Why?
| | Ligands | 1 | 2005 | 661 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2008 | 883 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2006 | 428 | 0.010 |
Why?
| | bcl-X Protein | 1 | 2002 | 42 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 317 | 0.010 |
Why?
| | Superantigens | 1 | 2002 | 69 | 0.010 |
Why?
| | Interleukin-3 | 1 | 2002 | 25 | 0.010 |
Why?
| | Receptors, CCR7 | 1 | 2002 | 32 | 0.010 |
Why?
| | Receptors, Chemokine | 1 | 2002 | 47 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 100 | 0.010 |
Why?
| | Chemokines, CXC | 1 | 2002 | 69 | 0.010 |
Why?
| | Genetic Variation | 1 | 2007 | 1000 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7559 | 0.010 |
Why?
| | Aging | 1 | 2011 | 1849 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 789 | 0.010 |
Why?
| | Phorbol Esters | 1 | 2000 | 14 | 0.010 |
Why?
| | Expressed Sequence Tags | 1 | 2000 | 42 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2000 | 136 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 1999 | 188 | 0.010 |
Why?
| | Abatacept | 1 | 1999 | 57 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1999 | 81 | 0.010 |
Why?
| | Hybridomas | 1 | 1999 | 236 | 0.010 |
Why?
| | Immunization, Secondary | 1 | 1999 | 87 | 0.010 |
Why?
| | Antioxidants | 1 | 2002 | 588 | 0.010 |
Why?
| | NF-kappa B | 1 | 2002 | 676 | 0.010 |
Why?
| | Hot Temperature | 1 | 2000 | 391 | 0.010 |
Why?
| | Databases, Factual | 1 | 2000 | 1367 | 0.010 |
Why?
|
|
Kedl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|